Abstract |
Vertex and Mitsubishi are developing VX-950 (LY-570310), the lead compound from a program of small-molecule inhibitors of the hepatitis C virus (HCV) NS3 protease, for the potential treatment of HCV infection. In November 2004, Vertex initiated a phase Ib European trial of VX-950 for the treatment of HCV infection.
|
Authors | Vincenzo Summa |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 6
Issue 8
Pg. 831-7
(Aug 2005)
ISSN: 1472-4472 [Print] England |
PMID | 16121690
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antiviral Agents
- NS3 protein, hepatitis C virus
- Oligopeptides
- Protease Inhibitors
- Viral Nonstructural Proteins
- telaprevir
|
Topics |
- Animals
- Antiviral Agents
(adverse effects, metabolism, pharmacokinetics, pharmacology, therapeutic use, toxicity)
- Humans
- Oligopeptides
(adverse effects, metabolism, pharmacokinetics, pharmacology, therapeutic use, toxicity)
- Patents as Topic
- Protease Inhibitors
(pharmacology, therapeutic use)
- Structure-Activity Relationship
- Viral Nonstructural Proteins
(antagonists & inhibitors)
|